U.S. court affirms Sanofi's Eloxatin patent until 2012

Sanofi's ($SNY) Eloxatin is safe from generic competition in the U.S. until August 2012. A federal court denied Sun Pharmaceuticals' appeal in a patent dispute over the colon cancer drug, which brought in $349 million in the the second quarter, Reuters said. Report